{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093933","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.632890+00:00","generated_at":"2026-05-31T10:55:18.559100+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xenon reports Q2 net loss of $57.9M; cash $850.6M; Phase 3 epilepsy data H2 2025","bullets":["Net loss for Q2 2024 was $57.9M, compared to $47.5M in Q2 2023.","Cash and marketable securities $850.6M as of June 30, 2024, down from $930.9M at Dec 31, 2023; cash runway into 2027.","Phase 3 X-TOLE2 top-line FOS data anticipated H2 2025; MDD Phase 3 study to start H2 2024.","R&D expenses $49.7M (Q2 2024) vs $44.0M (Q2 2023); G&A $19.4M vs $11.6M.","Pre-clinical Kv7 and Nav1.7 candidates advancing; multiple INDs expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093933","json":"https://secwatch.observer/filing/0000950170-24-093933.json","markdown":"https://secwatch.observer/filing/0000950170-24-093933.md","text":"https://secwatch.observer/filing/0000950170-24-093933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024093933/0000950170-24-093933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024093933/xene-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:55:18.559100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}